Partha Mitra, PhD
School of Medicine, University of Queensland, Translational Research Institute, Australia
Dr Partha Mitra has more than 15 years of research experience in the field of biomedical science, particularly focusing on cancer and infectious diseases and published several research papers, book chapters, editorials and review articles. Currently, he is working as a scientist at a biotech company, Vaxxas, to develop the nanotechnology-based method of vaccine delivery funded by major funding agencies such as WHO, Gates Foundation, and Merck
Dr.Mitra started his career as a post-doctoral researcher at the University of Massachusetts Medical School in the laboratory of Prof. Gary Stein where he performed a major breakthrough research in the field of mammalian transcription which helps to demonstrate the link between cell cycle regulatory cyclins and the G1/S transition point in mammalian cells. His contributions were very well appreciated was promoted to junior faculty members. As a senior post-doctoral researcher at the University of Queensland, Dr. Mitra developed a novel therapeutic model in estrogen positive breast cancer and became a recipient of a research project funded by Cancer Council Queensland and participated in significant academic and industry collaborations.
Before joining at the University of Queensland, Dr. Mitra worked more than two years as a senior team leader in a Switzerland based drug discovery company Evolva Biotech and led a team to work on several time bound projects funded by the National Institute of Health (USA) and the European Union. Dr. Mitra also generated several industry-academia collaborations.
Besides working as a scientist in Vaxxas, Dr. Mitra is currently involved in writing book chapters and review articles.